Trastuzumab-DM1: Building a Chemotherapy-Free Road in the Treatment of Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
作者： Steven J. Isakoff , José Baselga
关键词:
摘要: previously untreated acute myeloid leukemia. Blood 114:326, 2009 (abstr 790) 18. Borthakur G, Jabbour E, Wang X, et al: Effect of front-line therapy with fludarabine, cytarabine, filgrastim, and gemtuzumab ozogamicin (FLAG-GO) on outcome in core-binding factor associated myelogenous leukemia (CBFAML). J Clin Oncol 28:499s, 2010 6552) 19. Lo-Coco F, Cimino Breccia M, Gemtuzumab (Mylotarg) as a single agent for molecularly relapsed promyelocytic 104:1995-1999, 2004 20. Estey EH, Giles FJ, Beran Experience ozogamycin (“mylotarg”) all-trans retinoic acid 99:4222-4224, 2002 21. Diverio D, Sustained molecular remission after low dose gemtuzumab-ozogamicin elderly patients advanced Haematologica 92:1273-1274, 2007 22. Ravandi Jones Effective treatment all-trans-retinoic acid, arsenic trioxide, ozogamicin. 27:504-510, 23. Vogel CL, Cobleigh MA, Tripathy Efficacy safety trastuzumab first-line HER2-overexpressing metastatic breast cancer. 20:719-726, 24. Johnson JR, Cohen Sridhara R, Approval summary erlotinib locally or non-small cell lung cancer failure at least one prior chemotherapy regimen. Cancer Res 11:6414-6421, 2005
sci-hub.se 参考文章(32)
Peter F Bross, Julie Beitz, Gang Chen, Xiao Hong Chen, Eric Duffy, Lydia Kieffer, Sandip Roy, Rajeshwari Sridhara, Atiqur Rahman, Grant Williams, Richard Pazdur, None, Approval Summary: Gemtuzumab Ozogamicin in Relapsed Acute Myeloid Leukemia Clinical Cancer Research. ,vol. 7, pp. 1490- 1496 ,(2001)
Teemu T. Junttila, Robert W. Akita, Kathryn Parsons, Carter Fields, Gail D. Lewis Phillips, Lori S. Friedman, Deepak Sampath, Mark X. Sliwkowski, Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941 Cancer Cell. ,vol. 15, pp. 429- 440 ,(2009) , 10.1016/J.CCR.2009.03.020
T. Junttila, C. Fields, G. Li, L. Crocker, K. Parsons, L. Berry, K. Totpal, G. Lewis Phillips, M. Sliwkowski, 515 POSTER Trastuzumab-mertansine (T-DM1) retains all the mechanisms of action (MOA) of trastuzumab and is extremely effective in combination with docetaxel Ejc Supplements. ,vol. 6, pp. 163- ,(2008) , 10.1016/S1359-6349(08)72449-2
Gail D. Lewis Phillips, Guangmin Li, Debra L. Dugger, Lisa M. Crocker, Kathryn L. Parsons, Elaine Mai, Walter A. Blättler, John M. Lambert, Ravi V.J. Chari, Robert J. Lutz, Wai Lee T. Wong, Frederic S. Jacobson, Hartmut Koeppen, Ralph H. Schwall, Sara R. Kenkare-Mitra, Susan D. Spencer, Mark X. Sliwkowski, Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate Cancer Research. ,vol. 68, pp. 9280- 9290 ,(2008) , 10.1158/0008-5472.CAN-08-1776
Camellia W. Adams, David E. Allison, Kelly Flagella, Leonard Presta, Janet Clarke, Noel Dybdal, Kathleen McKeever, Mark X. Sliwkowski, Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunology, Immunotherapy. ,vol. 55, pp. 717- 727 ,(2006) , 10.1007/S00262-005-0058-X
S. Hurvitz, M. Pegram, L. Lin, D. Chan, H. Allen, R. Dichmann, C. Hagenstad, J. Barstis, R. Hermann, E. Hu, R. Moroose, S. Thomas, C. Vogel, N. Ryba, D. Elashoff, D. Slamon, Final Results of a Phase II Trial Evaluating Trastuzumab and Bevacizumab as First Line Treatment of HER2-Amplified Advanced Breast Cancer. Cancer Research. ,vol. 69, pp. 6094- 6094 ,(2009) , 10.1158/0008-5472.SABCS-09-6094
Neville Davidson, Vera Gorbounova, Johannes Isaac Raats, Dimosthenis Skarlos, Beth Newstat, Debasish Roychowdhury, Paolo Paoletti, Cristina Oliva, Stephen Rubin, Steven Stein, Charles E. Geyer, David Cameron, Michelle Casey, Michael Press, Deborah Lindquist, Tadeusz Pienkowski, C. Gilles Romieu, Stephen Chan, Agnieszka Jagiello-Gruszfeld, Bella Kaufman, John Crown, Arlene Chan, Mario Campone, Patrice Viens, A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses Breast Cancer Research and Treatment. ,vol. 112, pp. 533- 543 ,(2008) , 10.1007/S10549-007-9885-0
David B Agus, Robert W Akita, William D Fox, Gail D Lewis, Brian Higgins, Paul I Pisacane, Julie A Lofgren, Charles Tindell, Douglas P Evans, Krista Maiese, Howard I Scher, Mark X Sliwkowski, Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell. ,vol. 2, pp. 127- 137 ,(2002) , 10.1016/S1535-6108(02)00097-1
J. Baselga, J. Cortes, P. Fumoleau, T. Petrella, K. Gelmon, S. Verma, X. Pivot, G. Ross, T. Szado, L. Gianni, Pertuzumab and Trastuzumab: Re-Responses to 2 Biological Agents in Patients with HER2-Positive Breast Cancer Which Had Previously Progressed during Therapy with Each Agent Given Separately: A New Biological and Clinical Observation. Cancer Research. ,vol. 69, pp. 5114- 5114 ,(2009) , 10.1158/0008-5472.SABCS-09-5114
Patrice Chevallier, Jacques Delaunay, Pascal Turlure, Arnaud Pigneux, Mathilde Hunault, Richard Garand, Thierry Guillaume, Herve Avet-Loiseau, Nathalia Dmytruk, Stephane Girault, Noel Milpied, Norbert Ifrah, Mohamad Mohty, Jean-Luc Harousseau, Reply to K. Filanovsky et al Journal of Clinical Oncology. ,vol. 28, ,(2010) , 10.1200/JCO.2009.26.8680